LONDON AstraZeneca's immunotherapy drug Imfinzi has won crucial approval from U.S. regulators for use in lung cancer, opening up a multibillion-dollar market for a medicine that has so far lagged behind competitors.
- Malawi cholera cases pass 500, eight people dead
- Gilead wins reversal of $2.54 billion hepatitis C drug patent verdict
- Shares of Apricus tank after FDA declines to OK erectile dysfunction cream
- Novartis readies to auction U.S. generic pills business: sources
- U.S. faces shortage of developmental and behavioral pediatrics specialists
(Reuters Health) - What if someone who lived with the young man who unleashed one of the deadliest school shootings in U.S. history this week had been concerned that he might harm himself or others and removed his AR-15 rifle from his home?
(Reuters Health) - Even though elderly people have the highest rates of hospitalization and death from influenza, a U.S. study suggests that older patients may be less likely to get tested for flu in the hospital.
Reuters Health - Older adults with dementia may be less likely to get in car crashes when they’re required to renew their driver’s licenses in person, a U.S. study suggests.
TORONTO Canopy Growth Corp, one of the world's biggest medical marijuana producers, now wants to take on the world's pharmaceutical giants. | Video